- Home
- RELX vs EW Comparison
RELX vs EW Comparison
Compare RELX & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RELX | EW |
|---|---|---|
| Founded | 1903 | 1958 |
| Country | United Kingdom | United States |
| Employees | 37600 | N/A |
| Industry | Business Services | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.9B | 50.2B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | RELX | EW |
|---|---|---|
| Price | $33.85 | $82.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 21 |
| Target Price | N/A | ★ $96.47 |
| AVG Volume (30 Days) | 3.8M | ★ 4.0M |
| Earning Date | 02-12-2026 | 04-22-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.83 |
| Revenue | N/A | ★ $6,067,600,000.00 |
| Revenue This Year | $9.17 | $13.39 |
| Revenue Next Year | $6.23 | $9.78 |
| P/E Ratio | ★ $20.27 | $45.27 |
| Revenue Growth | N/A | ★ 11.55 |
| 52 Week Low | $27.57 | $65.94 |
| 52 Week High | $56.33 | $87.89 |
Technical Indicators
Market Signals| Indicator | RELX | EW |
|---|---|---|
| Relative Strength Index (RSI) | 47.74 | 49.23 |
| Support Level | $27.57 | $80.91 |
| Resistance Level | $35.84 | $87.22 |
| Average True Range (ATR) | 0.84 | 2.22 |
| MACD | 0.07 | -0.21 |
| Stochastic Oscillator | 15.68 | 34.68 |
Price Performance
Historical ComparisonAbout RELX RELX PLC PLC
RELX is a global provider of information-based analytics and decision tools for professional and business customers in various industries. The company serves sectors such as science and medical research, risk management, and legal. In addition, RELX organizes large-scale digital and face-to-face events such as industry trade shows. Around 60% of revenue is generated in North America and about 20% in Europe.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.